RecruitingNCT07046702
68Ga-MY6349 PET/CT in Solid Tumors
68Ga-MY6349 PET/CT in Solid Tumors and Compared With 18F-FDG PET/CT
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment
300 participants
Start Date
Dec 10, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET/CT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET/CT.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- adult patients (aged 18 years or older)
- patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)
- patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET/CT scans
- patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee
Exclusion Criteria2
- patients with pregnancy
- the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TEST68Ga-MY6349
Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07046702
Related Trials
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
NCT074893781 location
Study of ZGGS34 in Participants With Advanced Solid Tumors
NCT072581211 location
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
NCT063498371 location
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
NCT064413315 locations
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
NCT0598516116 locations